

MORRISON & FOERSTER LLP

Attorneys at Law
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 887-1500
Facsimile: (202) 887-0763

1998 NOV 19 P 5:15

To: Examiner D.C. Jones
USPTO

Facsimile: (703) 308-4556
Phone: (703) 308-4634

From: Kate H. Murashige

Date: November 19, 1998

We are transmitting a total of ¹³~~9~~ pages (including this page).
Original or hard copy to follow if this box is checked ☐.

If you do not receive all pages, please call (202) 877-8792 as soon as possible.


Preparer of this slip has confirmed that facsimile number given is correct: 6573/LRFB

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee), you may not copy, use, or distribute it. If you have received it in error, please advise Morrison & Foerster LLP immediately by telephone or facsimile and return it promptly by mail.

Comments: Attached is an Amendment Under 37 CFR § 1.111 for Serial No. 08/913,960. Thank you.

OFFICIAL**RECEIVED**
19 NOV 98**PATENT**
Docket No. 391442000200**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on November 19, 1998.


Lisa R.F. Barber**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

MURRER et al.

Serial No.: 08/913,960

Filing Date: 2 January 1998

For: **PHARMACEUTICAL COMPOSITION
CONTAINING SELECTED
LANTHANUM CARBONATE
HYDRATES**

Examiner: D.C. Jones

Group Art Unit: 1614

AMENDMENT UNDER 37 C.F.R. § 1.111Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to an Office action herein mailed 11 September 1998, time for response to which was set to expire 11 December 1998. The pending claims, claims 1-9 were rejected or objected to. Applicants appreciate the courtesy and thoughtfulness extended their undersigned representative in an interview regarding this application on 18 November 1998. The grounds for rejection have been carefully considered and the following amendment and discussion are offered in response. Indication at the interview of the allowability of the subject matter of claims 7 and 8 (method to prepare the claimed hydrates) and claims 10-13 (methods to treat hyperphosphataemia using the hydrates) is greatly appreciated. However, for completeness of the record, the following discussion addresses these claims as well as claims 1-3 and 5 (claims to pharmaceutical compositions). Reconsideration is respectfully requested.

dc-136963

#8/B
JRP
11/20/98